SLC35C1: A Potential Drug Target Or Biomarker for Neurological and Cardiovascular Diseases

Target Name: SLC35C1

NCBI ID: G55343

SLC35C1

SLC35C1: A Potential Drug Target Or Biomarker for Neurological and Cardiovascular Diseases

SLC35C1 (SLC35C1 variant 3) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the SLC family of transmembrane proteins, which are known for their ability to transport various molecules across the blood-brain barrier. SLC35C1 has been identified as a potential drug target or biomarker for various neurological and cardiovascular diseases, and research is ongoing to determine its utility in these fields.

SLC35C1 is a 21-kDa protein that is expressed in the brain, heart, and kidneys. It is a member of the SLC family of transmembrane proteins, which are characterized by the presence of a transmembrane protein that spans the entire cell membrane. SLC35C1 is made up of 21 amino acid residues and has a calculated pI of 8.1.

SLC35C1 is involved in various physiological processes in the body, including the regulation of ion and water transport. It is expressed in various tissues of the brain, including the prefrontal cortex, basal ganglia, and cerebellum. It is also expressed in the heart and kidneys, where it is involved in the regulation of ion and water transport in these organs.

SLC35C1 has been identified as a potential drug target or biomarker for various neurological and cardiovascular diseases. For example, research has shown that SLC35C1 is involved in the regulation of neurotransmitter release from the brain, and that it may play a role in the development of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

In addition to its potential role in neurodegenerative diseases, SLC35C1 has also been shown to be involved in the regulation of pain perception and neuroinflammation. For example, research has shown that SLC35C1 is involved in the regulation of pain perception and that it may play a role in the development of chronic pain conditions.

SLC35C1 has also been identified as a potential biomarker for various cardiovascular diseases, including heart failure and hypertension. For example, research has shown that SLC35C1 is expressed in the heart and that it may be involved in the regulation of ion and water transport in this organ.

In conclusion, SLC35C1 is a protein that is expressed in various tissues of the body and is involved in the regulation of ion and water transport. It has been identified as a potential drug target or biomarker for various neurological and cardiovascular diseases, and research is ongoing to determine its utility in these fields. Further research is needed to fully understand the role of SLC35C1 in these processes and to determine its potential as a drug or biomarker.

Protein Name: Solute Carrier Family 35 Member C1

Functions: Antiporter specific for GDP-l-fucose and depending on the concomitant reverse transport of GMP. Involved in GDP-fucose import from the cytoplasm into the Golgi lumen

The "SLC35C1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC35C1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets